CD274 and non-small cell lung carcinoma: <b>Methods</b>: We conducted a retrospective, single-center real-world study including patients with metastatic non-squamous NSCLC and PD-L1 TPS of 1-49% treated with first-line pembrolizumab plus pemetrexed-platinum chemotherapy between June 2024 and May 2025.